UK Approves First Oral Weight Loss Medication
英國批准首款口服減肥藥物
更新於: 2026年6月15日 上午02:30
On June 11, 2026, the UK made a significant medical breakthrough with the Medicines and Healthcare products Regulatory Agency (MHRA) approving the first oral GLP-1 receptor agonist for weight management.
2026年6月11日，英國在醫學上取得了一項重大突破，藥品和保健產品管理局(MHRA)批准了首款用於體重管理的口服GLP-1受體激動劑。
This new daily tablet version of semaglutide, branded as Wegovy, offers an alternative for patients who prefer pills over the previously required weekly injections.
這款名為Wegovy的全新每日口服司美格魯肽(semaglutide)錠劑，為那些比起每週注射更偏好服用藥丸的患者提供了另一種選擇。
This development is expected to make obesity treatment more accessible and less daunting for many.
此項發展預計將使肥胖症的治療變得更容易取得，且對許多人來說不再那麼令人望而生畏。
While currently available only through private prescription, the drug is intended for adults with a BMI of 30 or above, or those with a BMI of 27 to 30 with weight-related health conditions.
雖然目前僅能透過私人處方取得，但該藥物適用於BMI值在30以上的成人，或是BMI值介於27至30之間且患有與體重相關健康問題的患者。
To ensure effectiveness, the medication must be taken on an empty stomach after fasting for eight hours.
為確保療效，此藥物必須在禁食八小時後的空腹狀態下服用。
While effective—clinical trials showed a 13.6% average weight loss over 64 weeks—patients should expect common gastrointestinal side effects like nausea or diarrhea.
雖然效果顯著——臨床試驗顯示在64週內平均體重減輕了13.6%——但患者仍應預期會出現噁心或腹瀉等常見的胃腸道副作用。
This approval represents a major step forward in obesity care, provided it is managed safely through professional pharmacy channels.
此項批准代表著肥胖症治療的一大進步，前提是必須透過專業藥局管道安全地進行管理。
